Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B de Valk

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Archives of Internal Medicine|July 27, 1999
Iron, atherosclerosis, and ischemic heart diseaseB de Valk, J J Marx
European Journal of Clinical Investigation|March 12, 2002
Iron does not bind to the Apo-B protein of low-density lipoproteinB de Valk, F R Leus, H A M Voorbij, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 6, 2003
[A gastric signet ring cell carcinoma as the first expression of a breast carcinoma]F A R M Warmerdam, J L G Blaauwgeers, B de Valk, et al.
European Journal of Clinical Investigation|February 26, 2000
Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotesB de Valk, M A Addicks, I Gosriwatana, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 7, 2003
[Non-traumatic myositis ossificans circumscripta in the teres major muscle]J E Arends, P Drillenburg, H J van der Woude, et al.
British Journal of Cancer|July 17, 2003
Alveolar soft-part sarcoma responding to interferon alpha-2bK J Roozendaal, B de Valk, J J A ten Velden, et al.
Breast Cancer Research and Treatment|March 22, 2017
Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II studyKonstantinos Tryfonidis, S Marreaud, H Khaled, et al.
Circulation|September 24, 1999
Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in womenM Roest, Y T van der Schouw, B de Valk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2010
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patientsI E Smith, J-Y Pierga, L Biganzoli, et al.
British Journal of Haematology|November 3, 2025
Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myelomaM R Seefat, D G J Cucchi, L van Boven, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Archives of Internal Medicine|July 27, 1999
Iron, atherosclerosis, and ischemic heart diseaseB de Valk, J J Marx
European Journal of Clinical Investigation|March 12, 2002
Iron does not bind to the Apo-B protein of low-density lipoproteinB de Valk, F R Leus, H A M Voorbij, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 6, 2003
[A gastric signet ring cell carcinoma as the first expression of a breast carcinoma]F A R M Warmerdam, J L G Blaauwgeers, B de Valk, et al.
European Journal of Clinical Investigation|February 26, 2000
Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotesB de Valk, M A Addicks, I Gosriwatana, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 7, 2003
[Non-traumatic myositis ossificans circumscripta in the teres major muscle]J E Arends, P Drillenburg, H J van der Woude, et al.
British Journal of Cancer|July 17, 2003
Alveolar soft-part sarcoma responding to interferon alpha-2bK J Roozendaal, B de Valk, J J A ten Velden, et al.
Breast Cancer Research and Treatment|March 22, 2017
Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II studyKonstantinos Tryfonidis, S Marreaud, H Khaled, et al.
Circulation|September 24, 1999
Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in womenM Roest, Y T van der Schouw, B de Valk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2010
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patientsI E Smith, J-Y Pierga, L Biganzoli, et al.
British Journal of Haematology|November 3, 2025
Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myelomaM R Seefat, D G J Cucchi, L van Boven, et al.
Pageof 1